Right to Try Act of 2017
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Right to Try Act of 2017
This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are: (1) intended to treat a patient who has been diagnosed with a terminal illness, and (2) authorized by state law. The federal government must allow unrestricted possession and use of such treatments by patients certified by a physician as having exhausted all other treatment options.
A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment.
The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment.
The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration; and (3) not be approved, licensed, or cleared for sale under the Federal Food, Drug, or Cosmetic Act or the Public Health Service Act.
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 878: Right to Try Act of 2017. 115th Congress. Open America. https://openamerica.io/bill/115-HR-878/
"H.R. 878: Right to Try Act of 2017." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-878/.
H.R. 878, 115th Cong. (2026), https://openamerica.io/bill/115-HR-878/.
[H.R. 878: Right to Try Act of 2017](https://openamerica.io/bill/115-HR-878/)